Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
Non-small Cell Lung Cancer
DRUG: ISIS EIF4E Rx|DRUG: ISIS EIF4E Rx|DRUG: ISIS EIF4E Rx|DRUG: Paclitaxel|DRUG: Carboplatin
Progression free survival, At the end of each 21 day cycle
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.